Negative pressure wound therapy apparatus for post breast surgery wounds

BACKGROUND
Technical Field

Embodiments described herein relate to apparatuses, systems, and methods the treatment of wounds, for example using dressings in combination with negative pressure wound therapy, particularly for post-breast surgery wounds.

Description of the Related Art

The treatment of open or chronic wounds that are too large to spontaneously close or otherwise fail to heal by means of applying negative pressure to the site of the wound is well known in the art. Negative pressure wound therapy (NPWT) systems currently known in the art commonly involve placing a cover that is impermeable or semi-permeable to fluids over the wound, using various means to seal the cover to the tissue of the patient surrounding the wound, and connecting a source of negative pressure (such as a vacuum pump) to the cover in a manner so that negative pressure is created and maintained under the cover. It is believed that such negative pressures promote wound healing by facilitating the formation of granulation tissue at the wound site and assisting the body's normal inflammatory process while simultaneously removing excess fluid, which may contain adverse cytokines and/or bacteria. However, further improvements in NPWT are needed to fully realize the benefits of treatment.

Many different types of wound dressings are known for aiding in NPWT systems. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. One example of a multi-layer wound dressing is the PICO dressing, available from Smith & Nephew, which includes a superabsorbent layer beneath a backing layer to provide a canister-less system for treating a wound with NPWT. The wound dressing may be sealed to a suction port providing connection to a length of tubing, which may be used to pump fluid out of the dressing and/or to transmit negative pressure from a pump to the wound dressing.

Certain wounds have shapes that are difficult to treat with negative pressure wound therapy. It may be desirable, in some situations, to provide a wound dressing shaped to fit a specific region of the body or wound type so that it is shaped and contoured around that area allowing full coverage and even application of negative pressure throughout the treatment area. For example, it can be difficult to apply a standard wound dressing to post-breast surgery wounds.

SUMMARY

Embodiments of the present disclosure relate to apparatuses and methods for wound treatment. Some of the wound treatment apparatuses described herein comprise a negative pressure source or a pump system for providing negative pressure to a wound. Wound treatment apparatuses may also comprise wound dressings that may be used in combination with the negative pressure sources and pump assemblies described herein. In some embodiments, one or more dressings can be used to treat one or more surgical wounds including post-breast surgery wounds.

In some aspects, a negative pressure wound therapy apparatus is provided, comprising: a wound dressing comprising an elongate portion having a longitudinal axis and a bridging portion, wherein the bridging portion comprises a first end and a second end, wherein the bridging portion extends away from a middle portion of the elongate portion at a substantially right angle from the longitudinal axis at the first end of the bridging portion, the wound dressing comprising within both the elongate portion and the bridging portion: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture at a second end of the bridging portion; and a fluidic connector positioned over the aperture in the cover layer at the second end of the bridging portion.

In another aspect, a negative pressure wound therapy apparatus is provided, comprising: a wound dressing comprising an elongate portion comprising two lobes and a bridging portion, wherein the elongate portion comprises a longitudinal axis and the bridging portion is positioned in a middle portion of the elongate portion along the longitudinal axis, a first lobe on a first side of the bridging portion and a second lobe on a second side of the bridging portion, the wound dressing comprising within both the elongate portion and the bridging portion: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture in the bridging portion; and a fluidic connector positioned over the aperture in the cover layer at the bridging portion.

The apparatus of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. In some embodiments, the first and second lobes comprise a substantially triangular shape having edges and corners. In some embodiments, the first and second lobes comprise a long edge shared between the first triangular shaped lobe and the second triangular shaped lobe. In some embodiments, the first and second lobes comprise a substantially oval or circular shape. In some embodiments, the absorbent layer/and or transmission layer is a continuous layer between the bridging portion and the elongate portion. In some embodiments, the bridging portion is rectangular and extends perpendicularly away from the elongate portion. In some embodiments, the wound contact layer is a single sheet of material across the elongate portion and the bridging portion. In some embodiments, the cover layer is a single sheet of material across the elongate portion and the bridging portion. In some embodiments, the one or more lobes are sized and configured to cover one or more post-surgical breast wounds, with the bridging portion being located between the breasts.

In another aspect, a negative pressure wound therapy apparatus is provided, comprising: a wound dressing comprising an elongate portion having a longitudinal axis and a bridging portion, wherein the bridging portion comprises a first end and a second end, wherein the bridging portion extends away from a middle portion of the elongate portion at a substantially right angle from the longitudinal axis at the first end of the bridging portion, the wound dressing comprising within both the elongate portion and the bridging portion: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture at a second end of the bridging portion; and a fluidic connector positioned over the aperture in the cover layer at the second end of the bridging portion; wherein the elongate portion and the bridging portion are sized and configured to cover one or more post-surgical breast wounds, with the elongate portion and the bridging portion sized and configured to be located on a single breast.

The apparatus of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. In some embodiments, the elongate portion is rectangular having a length parallel to the longitudinal axis and a width perpendicular to the longitudinal axis, wherein the length is greater than the width. In some embodiments, the absorbent layer/and or transmission layer is a continuous layer between the bridging portion and the elongate portion. In some embodiments, the bridging portion is rectangular. In some embodiments, the wound contact layer is a single sheet of material across the elongate portion and the bridging portion. In some embodiments, the cover layer is a single sheet of material across the elongate portion and the bridging portion. In some embodiments, the wound dressing is a first wound dressing and the fluid connector is a first fluid connector, and further comprises a second wound dressing comprising an elongate portion having a longitudinal axis and a bridging portion, wherein the bridging portion comprises a first end and a second end, wherein the bridging portion extends away from a middle portion of the elongate portion at a substantially right angle from the longitudinal axis at the first end of the bridging portion, the second wound dressing comprising within both the elongate portion and the bridging portion: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture at a second end of the bridging portion; and a second fluidic connector positioned over the aperture in the cover layer of the second wound dressing at the second end of the bridging portion of the second wound dressing; wherein the elongate portion and the bridging portion of the second wound dressing are sized and configured to cover one or more post-surgical breast wounds, with the elongate portion and the bridging portion of the second wound dressing sized and configured to be located on a different breast than that of the first wound dressing. In some embodiments, the first fluidic connector and the second fluidic connector are configured to be connected to a single negative pressure source via a Y-shaped connector.

In another aspect, a negative pressure wound therapy apparatus is provided, comprising: a wound dressing comprising a triangular shape, the wound dressing having three edges and three corners, the wound dressing comprising: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture positioned near an edge of the triangular shaped dressing; and a fluidic connector positioned over the aperture in the cover layer near the edge of the triangular shaped dressing.

The apparatus of the preceding paragraph may also include any combination of the following features described in this paragraph, among others described herein. In some embodiments, the wound dressing is sized and configured to cover one or more post-surgical breast wounds, wherein the dressing is configured to cover a single breast. In some embodiments, the wound dressing is a first wound dressing and the fluidic connector is a first fluid connector, and further comprises a second wound dressing comprising a triangular shape, the second wound dressing having three edges and three corners, the second wound dressing comprising: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture positioned near an edge of the triangular shaped dressing; and a second fluidic connector positioned over the aperture in the cover layer of the second wound dressing near the edge of the second triangular shaped dressing. In some embodiments, the second wound dressing is sized and configured to cover one or more post-surgical breast wounds, wherein the second dressing is configured to cover a different breast than that of the first wound dressing. In some embodiments, the first fluidic connector and the second fluidic connector are configured to be connected to a single negative pressure source via a Y-shaped connector.

In other aspects, a negative pressure wound therapy apparatus is provided which comprises a first wound dressing and a second wound dressing, each wound dressing sized and configured to be located on different breasts. In some embodiments, the apparatus comprises a Y-shaped connector configured to connect to the first and second wound dressings, for example via first and second fluidic connectors positioned in fluid communication with the first and second wound dressings, respectively. A single negative pressure source may be provided to connect to the Y-shaped connector to provide negative pressure simultaneously to both the first and second wound dressings.

In some embodiments, each of the first and second wound dressings may comprise an elongate portion having a longitudinal axis and a bridging portion, wherein the bridging portion comprises a first end and a second end, wherein the bridging portion extends away from a middle portion of the elongate portion at a substantially right angle from the longitudinal axis at the first end of the bridging portion. Each of the first and second wound dressings may comprise within the elongate portion and the bridging portion: a wound contact layer configured to be positioned in contact with a wound; an absorbent layer and/or transmission layer over the wound contact layer; and a cover layer configured to cover and form a seal over the wound contact layer and the absorbent layer and/or transmission layer, wherein the cover layer comprises an aperture at a second end of the bridging portion. First and second fluidic connectors may be positioned over the aperture in the cover layer of the first and second wound dressings, respectively, at the second end of the bridging portion. The elongate portion and the bridging portion of each of the first and second wound dressings may be sized and configured to cover one or more post-surgical breast wounds of different breasts.

Any of the features, components, or details of any of the arrangements or embodiments disclosed in this application, including without limitation any of the pump embodiments and any of the negative pressure wound therapy embodiments disclosed below, are interchangeably combinable with any other features, components, or details of any of the arrangements or embodiments disclosed herein to form new arrangements and embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A illustrates an embodiment of a negative pressure wound treatment system employing a flexible fluidic connector and a wound dressing capable of absorbing and storing wound exudate;

FIG. 1B illustrates an embodiment of a negative pressure wound treatment system employing a flexible fluidic connector and a wound dressing capable of absorbing and storing wound exudate;

FIG. 2A illustrates an embodiment of a negative pressure wound treatment system employing a flexible fluidic connector and a wound dressing capable of absorbing and storing wound exudate;

FIG. 2B illustrates a cross section of an embodiment of a fluidic connector connected to a wound dressing;

FIG. 3A illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a T shape;

FIG. 3B illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a two lobe T shape;

FIG. 3C illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a T shape;

FIG. 3D illustrates surgical incisions post breast surgery;

FIG. 3E illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a two circular lobe shape;

FIG. 3F illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a two triangular lobe shape;

FIG. 3G illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a triangular shape; and

FIGS. 4A-D illustrate the use and application of an embodiment of a wound treatment system onto a patient.

FIGS. 5A and 5B illustrate an embodiment of a Y-shaped connector for a multisite dressing.

FIG. 5C illustrates an embodiment of a Y-shaped connector that is formed of two parts.

DETAILED DESCRIPTION

Embodiments disclosed herein relate to apparatuses and methods of treating a wound with reduced pressure, including a source of negative pressure and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to herein as dressings.

Preferred embodiments disclosed herein relate to wound therapy for a human or animal body. Therefore, any reference to a wound herein can refer to a wound on a human or animal body, and any reference to a body herein can refer to a human or animal body. The term “wound” as used herein, in addition to having its broad ordinary meaning, includes any body part of a patient that may be treated using negative pressure. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, abdominal wounds or other large or incisional wounds, either as a result of surgery, trauma, sterniotomies, fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic wounds, subacute and dehisced wounds, traumatic wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like.

Treatment of such wounds can be performed using negative pressure wound therapy, wherein a reduced or negative pressure can be applied to the wound to facilitate and promote healing of the wound. It will also be appreciated that the wound dressing and methods as disclosed herein may be applied to other parts of the body, and are not necessarily limited to treatment of wounds.

It will be understood that embodiments of the present disclosure are generally applicable to use in topical negative pressure (“TNP”) therapy systems. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of “hard to heal” wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and thus infection risk). In addition, the therapy allows for less disturbance of a wound leading to more rapid healing. TNP therapy systems may also assist on the healing of surgically closed wounds by removing fluid and by helping to stabilize the tissue in the apposed position of closure. A further beneficial use of TNP therapy can be found in grafts and flaps where removal of excess fluid is important and close proximity of the graft to tissue is required in order to ensure tissue viability.

As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels relative to normal ambient atmospheric pressure, which can correspond to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg). In some embodiments, local ambient atmospheric pressure is used as a reference point, and such local atmospheric pressure may not necessarily be, for example, 760 mmHg.

The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −20 mmHg and −200 mmHg. Note that these pressures are relative to normal ambient atmospheric pressure, which can be 760 mmHg. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even −150 mmHg, can be supplied by the negative pressure apparatus.

In some embodiments of wound closure devices described herein, increased wound contraction can lead to increased tissue expansion in the surrounding wound tissue. This effect may be increased by varying the force applied to the tissue, for example by varying the negative pressure applied to the wound over time, possibly in conjunction with increased tensile forces applied to the wound via embodiments of the wound closure devices. In some embodiments, negative pressure may be varied over time for example using a sinusoidal wave, square wave, and/or in synchronization with one or more patient physiological indices (e.g., heartbeat). Examples of such applications where additional disclosure relating to the preceding may be found include U.S. Pat. No. 8,235,955, titled “Wound treatment apparatus and method,” issued on Aug. 7, 2012; and U.S. Pat. No. 7,753,894, titled “Wound cleansing apparatus with stress,” issued Jul. 13, 2010. The disclosures of both of these patents are hereby incorporated by reference in their entirety.

Embodiments of the wound dressings, wound dressing components, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in International Application No. PCT/IB2013/001469, filed May 22, 2013, published as WO 2013/175306 A2 on Nov. 28, 2013, titled “APPARATUSES AND METHODS FOR NEGATIVE PRESSURE WOUND THERAPY,” U.S. patent application Ser. No. 14/418,874, filed Jan. 30, 2015, published as US 2015/0190286 A1 on Jul. 9, 2015, titled “WOUND DRESSING AND METHOD OF TREATMENT,” the disclosures of which are hereby incorporated by reference in their entireties. Embodiments of the wound dressings, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in U.S. patent application Ser. No. 13/092,042, filed Apr. 21 2011, published as US2011/0282309, titled “WOUND DRESSING AND METHOD OF USE,” and U.S. patent application Ser. No. 14/715,527, filed May 18, 2015, titled “FLUIDIC CONNECTOR FOR NEGATIVE PRESSURE WOUND THERAPY,” the disclosures of which are hereby incorporated by reference in its entirety, including further details relating to embodiments of wound dressings, the wound dressing components and principles, and the materials used for the wound dressings.

Additionally, some embodiments related to TNP wound treatment comprising a wound dressing in combination with a pump and/or associated electronics described herein may also be used in combination or in addition to those described in PCT Application No. PCT/EP2016/059329, filed Apr. 26, 2016, entitled “REDUCED PRESSURE APPARATUS AND METHODS”.

FIGS. 1A-B illustrate embodiments of a negative pressure wound treatment system 10 employing a wound dressing 100 in conjunction with a fluidic connector 110. Here, the fluidic connector 110 may comprise an elongate conduit, more preferably a bridge 120 having a proximal end 130 and a distal end 140, and an applicator 180 at the distal end 140 of the bridge 120. An optional coupling 160 is preferably disposed at the proximal end 130 of the bridge 120. A cap 170 may be provided with the system (and can in some cases, as illustrated, be attached to the coupling 160). The cap 170 can be useful in preventing fluids from leaking out of the proximal end 130. The system 10 may include a source of negative pressure such as a pump or negative pressure unit 150 capable of supplying negative pressure. The pump may comprise a canister or other container for the storage of wound exudates and other fluids that may be removed from the wound. A canister or container may also be provided separate from the pump. In some embodiments, such as illustrated in FIGS. 1A-1B, the pump 150 can be a canisterless pump such as the PICO™ pump, as sold by Smith & Nephew. The pump 150 may be connected to the coupling 160 via a tube 190, or the pump 150 may be connected directly to the coupling 160 or directly to the bridge 120. In use, the dressing 100 is placed over a suitably-prepared wound, which may in some cases be filled with a wound packing material such as foam or gauze. The applicator 180 of the fluidic connector 110 has a sealing surface that is placed over an aperture in the dressing 100 and is sealed to the top surface of the dressing 100. In other embodiments, the fluidic connector 110 that is positioned over the aperture in the dressing can also include a fluidic connector 110 that has a portion of the fluidic connector 110 positioned on the underside of the top layer or cover layer of the dressing. In some embodiments, the fluidic connector can include a flange that can be attached to the underside or top surface of the cover layer. Either before, during, or after connection of the fluidic connector 110 to the dressing 100, the pump 150 is connected via the tube 190 to the coupling 160, or is connected directly to the coupling 160 or to the bridge 120. The pump is then activated, thereby supplying negative pressure to the wound. Application of negative pressure may be applied until a desired level of healing of the wound is achieved.

As shown in FIG. 2A, the fluidic connector 110 preferably comprises an enlarged distal end, or head 140 that is in fluidic communication with the dressing 100 as will be described in further detail below. In one embodiment, the enlarged distal end has a round or circular shape. The head 140 is illustrated here as being positioned near an edge of the dressing 100, but may also be positioned at any location on the dressing. For example, some embodiments may provide for a centrally or off-centered location not on or near an edge or corner of the dressing 100. In some embodiments, the dressing 10 may comprise two or more fluidic connectors 110, each comprising one or more heads 140, in fluidic communication therewith. In a preferred embodiment, the head 140 may measure 30mm along its widest edge. The head 140 forms at least in part the applicator 180, described above, that is configured to seal against a top surface of the wound dressing.

FIG. 2B illustrates a cross-section through a wound dressing 100 similar to the wound dressing 10 as shown in FIG. 1B and described in International Patent Publication WO2013175306 A2, which is incorporated by reference in its entirety, along with fluidic connector 110. The wound dressing 100, which can alternatively be any wound dressing embodiment disclosed herein or any combination of features of any number of wound dressing embodiments disclosed herein, can be located over a wound site to be treated. The dressing 100 may be placed as to form a sealed cavity over the wound site. In a preferred embodiment, the dressing 100 comprises a top or cover layer, or backing layer 220 attached to an optional wound contact layer 222, both of which are described in greater detail below. These two layers 220, 222 are preferably joined or sealed together so as to define an interior space or chamber. This interior space or chamber may comprise additional structures that may be adapted to distribute or transmit negative pressure, store wound exudate and other fluids removed from the wound, and other functions which will be explained in greater detail below. Examples of such structures, described below, include a transmission layer 226 and an absorbent layer 221.

As used herein the upper layer, top layer, or layer above refers to a layer furthest from the surface of the skin or wound while the dressing is in use and positioned over the wound. Accordingly, the lower surface, lower layer, bottom layer, or layer below refers to the layer that is closest to the surface of the skin or wound while the dressing is in use and positioned over the wound.

As illustrated in FIG. 2B, the wound contact layer 222 can be a polyurethane layer or polyethylene layer or other flexible layer which is perforated, for example via a hot pin process, laser ablation process, ultrasound process or in some other way or otherwise made permeable to liquid and gas. The wound contact layer 222 has a lower surface 224 and an upper surface 223. The perforations 225 preferably comprise through holes in the wound contact layer 222 which enable fluid to flow through the layer 222. The wound contact layer 222 helps prevent tissue ingrowth into the other material of the wound dressing. Preferably, the perforations are small enough to meet this requirement while still allowing fluid to flow therethrough. For example, perforations formed as slits or holes having a size ranging from 0.025 mm to 1.2 mm are considered small enough to help prevent tissue ingrowth into the wound dressing while allowing wound exudate to flow into the dressing. In some configurations, the wound contact layer 222 may help maintain the integrity of the entire dressing 100 while also creating an air tight seal around the absorbent pad in order to maintain negative pressure at the wound.

Some embodiments of the wound contact layer 222 may also act as a carrier for an optional lower and upper adhesive layer (not shown). For example, a lower pressure sensitive adhesive may be provided on the lower surface 224 of the wound dressing 100 whilst an upper pressure sensitive adhesive layer may be provided on the upper surface 223 of the wound contact layer. The pressure sensitive adhesive, which may be a silicone, hot melt, hydrocolloid or acrylic based adhesive or other such adhesives, may be formed on both sides or optionally on a selected one or none of the sides of the wound contact layer. When a lower pressure sensitive adhesive layer is utilized may be helpful to adhere the wound dressing 100 to the skin around a wound site. In some embodiments, the wound contact layer may comprise perforated polyurethane film. The lower surface of the film may be provided with a silicone pressure sensitive adhesive and the upper surface may be provided with an acrylic pressure sensitive adhesive, which may help the dressing maintain its integrity. In some embodiments, a polyurethane film layer may be provided with an adhesive layer on both its upper surface and lower surface, and all three layers may be perforated together.

A layer 226 of porous material can be located above the wound contact layer 222. This porous layer, or transmission layer, 226 allows transmission of fluid including liquid and gas away from a wound site into upper layers of the wound dressing. In particular, the transmission layer 226 preferably ensures that an open air channel can be maintained to communicate negative pressure over the wound area even when the absorbent layer has absorbed substantial amounts of exudates. The layer 226 should preferably remain open under the typical pressures that will be applied during negative pressure wound therapy as described above, so that the whole wound site sees an equalized negative pressure. The layer 226 may be formed of a material having a three dimensional structure. For example, a knitted or woven spacer fabric (for example Baltex 7970 weft knitted polyester) or a non-woven fabric could be used.

In some embodiments, the transmission layer 226 comprises a 3D polyester spacer fabric layer including a top layer (that is to say, a layer distal from the wound-bed in use) which is a 84/144 textured polyester, and a bottom layer (that is to say, a layer which lies proximate to the wound bed in use) which is a 10 denier flat polyester and a third layer formed sandwiched between these two layers which is a region defined by a knitted polyester viscose, cellulose or the like mono filament fiber. Other materials and other linear mass densities of fiber could of course be used.

Whilst reference is made throughout this disclosure to a monofilament fiber it will be appreciated that a multistrand alternative could of course be utilized. The top spacer fabric thus has more filaments in a yarn used to form it than the number of filaments making up the yarn used to form the bottom spacer fabric layer.

This differential between filament counts in the spaced apart layers helps control moisture flow across the transmission layer. Particularly, by having a filament count greater in the top layer, that is to say, the top layer is made from a yarn having more filaments than the yarn used in the bottom layer, liquid tends to be wicked along the top layer more than the bottom layer. In use, this differential tends to draw liquid away from the wound bed and into a central region of the dressing where the absorbent layer 221 helps lock the liquid away or itself wicks the liquid onwards towards the cover layer where it can be transpired.

Preferably, to improve the liquid flow across the transmission layer 226 (that is to say perpendicular to the channel region formed between the top and bottom spacer layers, the 3D fabric may be treated with a dry cleaning agent (such as, but not limited to, Perchloro Ethylene) to help remove any manufacturing products such as mineral oils, fats and/or waxes used previously which might interfere with the hydrophilic capabilities of the transmission layer. In some embodiments, an additional manufacturing step can subsequently be carried in which the 3D spacer fabric is washed in a hydrophilic agent (such as, but not limited to, Feran Ice 30 g/l available from the Rudolph Group). This process step helps ensure that the surface tension on the materials is so low that liquid such as water can enter the fabric as soon as it contacts the 3D knit fabric. This also aids in controlling the flow of the liquid insult component of any exudates.

A layer 221 of absorbent material is provided above the transmission layer 226. The absorbent material, which comprise a foam or non-woven natural or synthetic material, and which may optionally comprise a super-absorbent material, forms a reservoir for fluid, particularly liquid, removed from the wound site. In some embodiments, the layer 10 may also aid in drawing fluids towards the backing layer 220.

The material of the absorbent layer 221 may also prevent liquid collected in the wound dressing 100 from flowing freely within the dressing, and preferably acts so as to contain any liquid collected within the dressing. The absorbent layer 221 also helps distribute fluid throughout the layer via a wicking action so that fluid is drawn from the wound site and stored throughout the absorbent layer. This helps prevent agglomeration in areas of the absorbent layer. The capacity of the absorbent material must be sufficient to manage the exudates flow rate of a wound when negative pressure is applied. Since in use the absorbent layer experiences negative pressures the material of the absorbent layer is chosen to absorb liquid under such circumstances. A number of materials exist that are able to absorb liquid when under negative pressure, for example superabsorber material. The absorbent layer 221 may typically be manufactured from ALLEVYN™ foam, Freudenberg 114-224-4 and/or Chem-Posite™11C-450. In some embodiments, the absorbent layer 221 may comprise a composite comprising superabsorbent powder, fibrous material such as cellulose, and bonding fibers. In a preferred embodiment, the composite is an airlaid, thermally-bonded composite.

In some embodiments, the absorbent layer 221 is a layer of non-woven cellulose fibers having super-absorbent material in the form of dry particles dispersed throughout. Use of the cellulose fibers introduces fast wicking elements which help quickly and evenly distribute liquid taken up by the dressing. The juxtaposition of multiple strand-like fibers leads to strong capillary action in the fibrous pad which helps distribute liquid. In this way, the super-absorbent material is efficiently supplied with liquid. The wicking action also assists in bringing liquid into contact with the upper cover layer to aid increase transpiration rates of the dressing.

An aperture, hole, or orifice 227 is preferably provided in the backing layer 220 to allow a negative pressure to be applied to the dressing 100. The fluidic connector 110 is preferably attached or sealed to the top of the backing layer 220 over the orifice 227 made into the dressing 100, and communicates negative pressure through the orifice 227. A length of tubing may be coupled at a first end to the fluidic connector 110 and at a second end to a pump unit (not shown) to allow fluids to be pumped out of the dressing. Where the fluidic connector is adhered to the top layer of the wound dressing, a length of tubing may be coupled at a first end of the fluidic connector such that the tubing, or conduit, extends away from the fluidic connector parallel or substantially to the top surface of the dressing. The fluidic connector 110 may be adhered and sealed to the backing layer 220 using an adhesive such as an acrylic, cyanoacrylate, epoxy, UV curable or hot melt adhesive. The fluidic connector 110 may be formed from a soft polymer, for example a polyethylene, a polyvinyl chloride, a silicone or polyurethane having a hardness of 30 to 90 on the Shore A scale. In some embodiments, the fluidic connector 110 may be made from a soft or conformable material.

Preferably the absorbent layer 221 includes at least one through hole 228 located so as to underlie the fluidic connector 110. The through hole 228 may in some embodiments be the same size as the opening 227 in the backing layer, or may be bigger or smaller. As illustrated in FIG. 2B a single through hole can be used to produce an opening underlying the fluidic connector 110. It will be appreciated that multiple openings could alternatively be utilized. Additionally, should more than one port be utilized according to certain embodiments of the present disclosure one or multiple openings may be made in the absorbent layer and the obscuring layer in registration with each respective fluidic connector. Although not essential to certain embodiments of the present disclosure the use of through holes in the super-absorbent layer may provide a fluid flow pathway which remains unblocked in particular when the absorbent layer is near saturation.

The aperture or through-hole 228 is preferably provided in the absorbent layer 221 beneath the orifice 227 such that the orifice is connected directly to the transmission layer 226 as illustrated in FIG. 2B. This allows the negative pressure applied to the fluidic connector 110 to be communicated to the transmission layer 226 without passing through the absorbent layer 221. This ensures that the negative pressure applied to the wound site is not inhibited by the absorbent layer as it absorbs wound exudates. In other embodiments, no aperture may be provided in the absorbent layer 221, or alternatively a plurality of apertures underlying the orifice 227 may be provided. In further alternative embodiments, additional layers such as another transmission layer or an obscuring layer such as described in International Patent Publication WO2014020440, the entirety of which is hereby incorporated by reference, may be provided over the absorbent layer 221 and beneath the backing layer 220.

The backing layer 220 is preferably gas impermeable, but moisture vapor permeable, and can extend across the width of the wound dressing 100. The backing layer 220, which may for example be a polyurethane film (for example, Elastollan SP9109) having a pressure sensitive adhesive on one side, is impermeable to gas and this layer thus operates to cover the wound and to seal a wound cavity over which the wound dressing is placed. In this way an effective chamber is made between the backing layer 220 and a wound site where a negative pressure can be established. The backing layer 220 is preferably sealed to the wound contact layer 222 in a border region around the circumference of the dressing, ensuring that no air is drawn in through the border area, for example via adhesive or welding techniques. The backing layer 220 protects the wound from external bacterial contamination (bacterial barrier) and allows liquid from wound exudates to be transferred through the layer and evaporated from the film outer surface. The backing layer 220 preferably comprises two layers; a polyurethane film and an adhesive pattern spread onto the film. The polyurethane film is preferably moisture vapor permeable and may be manufactured from a material that has an increased water transmission rate when wet. In some embodiments the moisture vapor permeability of the backing layer increases when the backing layer becomes wet. The moisture vapor permeability of the wet backing layer may be up to about ten times more than the moisture vapor permeability of the dry backing layer.

The absorbent layer 221 may be of a greater area than the transmission layer 226, such that the absorbent layer overlaps the edges of the transmission layer 226, thereby ensuring that the transmission layer does not contact the backing layer 220. This provides an outer channel of the absorbent layer 221 that is in direct contact with the wound contact layer 222, which aids more rapid absorption of exudates to the absorbent layer. Furthermore, this outer channel ensures that no liquid is able to pool around the circumference of the wound cavity, which may otherwise seep through the seal around the perimeter of the dressing leading to the formation of leaks. As illustrated in FIGS. 2A-2B, the absorbent layer 221 may define a smaller perimeter than that of the backing layer 220, such that a boundary or border region is defined between the edge of the absorbent layer 221 and the edge of the backing layer 220.

As shown in FIG. 2B, one embodiment of the wound dressing 100 comprises an aperture 228 in the absorbent layer 221 situated underneath the fluidic connector 110. In use, for example when negative pressure is applied to the dressing 100, a wound facing portion of the fluidic connector may thus come into contact with the transmission layer 226, which can thus aid in transmitting negative pressure to the wound site even when the absorbent layer 221 is filled with wound fluids. Some embodiments may have the backing layer 220 be at least partly adhered to the transmission layer 226. In some embodiments, the aperture 228 is at least 1-2 mm larger than the diameter of the wound facing portion of the fluidic connector 11, or the orifice 227.

In particular for embodiments with a single fluidic connector 110 and through hole, it may be preferable for the fluidic connector 110 and through hole to be located in an off-center position as illustrated in FIG. 2A. Such a location may permit the dressing 100 to be positioned onto a patient such that the fluidic connector 110 is raised in relation to the remainder of the dressing 100. So positioned, the fluidic connector 110 and the filter 214 may be less likely to come into contact with wound fluids that could prematurely occlude the filter 214 so as to impair the transmission of negative pressure to the wound site.

Turning now to the fluidic connector 110, preferred embodiments comprise a sealing surface 216, a bridge 211 (corresponding to bridge 120 in FIGS. 1A-1B) with a proximal end 130 and a distal end 140, and a filter 214. The sealing surface 216 preferably forms the applicator previously described that is sealed to the top surface of the wound dressing. In some embodiments a bottom layer of the fluidic connector 110 may comprise the sealing surface 216. The fluidic connector 110 may further comprise an upper surface vertically spaced from the sealing surface 216, which in some embodiments is defined by a separate upper layer of the fluidic connector. In other embodiments the upper surface and the lower surface may be formed from the same piece of material. In some embodiments the sealing surface 216 may comprise at least one aperture 229 therein to communicate with the wound dressing. In some embodiments the filter 214 may be positioned across the opening 229 in the sealing surface, and may span the entire opening 229. The sealing surface 216 may be configured for sealing the fluidic connector to the cover layer of the wound dressing, and may comprise an adhesive or weld. In some embodiments, the sealing surface 216 may be placed over an orifice in the cover layer with optional spacer elements 215 configured to create a gap between the filter 214 and the transmission layer 226. In other embodiments, the sealing surface 216 may be positioned over an orifice in the cover layer and an aperture in the absorbent layer 220, permitting the fluidic connector 110 to provide air flow through the transmission layer 226. In some embodiments, the bridge 211 may comprise a first fluid passage 212 in communication with a source of negative pressure, the first fluid passage 212 comprising a porous material, such as a 3D knitted material, which may be the same or different than the porous layer 226 described previously. The bridge 211 is preferably encapsulated by at least one flexible film layer 208, 210 having a proximal and distal end and configured to surround the first fluid passage 212, the distal end of the flexible film being connected the sealing surface 216. The filter 214 is configured to substantially prevent wound exudate from entering the bridge, and spacer elements 215 are configured to prevent the fluidic connector from contacting the transmission layer 226. These elements will be described in greater detail below.

Some embodiments may further comprise an optional second fluid passage positioned above the first fluid passage 212. For example, some embodiments may provide for an air leak may be disposed at the proximal end of the top layer that is configured to provide an air path into the first fluid passage 212 and dressing 100 similar to the suction adapter as described in U.S. Pat. No. 8,801,685, which is incorporated by reference herein in its entirety.

Preferably, the fluid passage 212 is constructed from a compliant material that is flexible and that also permits fluid to pass through it if the spacer is kinked or folded over. Suitable materials for the fluid passage 212 include without limitation foams, including open-cell foams such as polyethylene or polyurethane foam, meshes, 3D knitted fabrics, non-woven materials, and fluid channels. In some embodiments, the fluid passage 212 may be constructed from materials similar to those described above in relation to the transmission layer 226. Advantageously, such materials used in the fluid passage 212 not only permit greater patient comfort, but may also provide greater kink resistance, such that the fluid passage 212 is still able to transfer fluid from the wound toward the source of negative pressure while being kinked or bent.

In some embodiments, the fluid passage 212 may be comprised of a wicking fabric, for example a knitted or woven spacer fabric (such as a knitted polyester 3D fabric, Baltex 7970®, or Gehring 879®) or a nonwoven fabric. These materials selected are preferably suited to channeling wound exudate away from the wound and for transmitting negative pressure and/or vented air to the wound site, and may also confer a degree of kinking or occlusion resistance to the fluid passage 212. In some embodiments, the wicking fabric may have a three-dimensional structure, which in some cases may aid in wicking fluid or transmitting negative pressure. In certain embodiments, including wicking fabrics, these materials remain open and capable of communicating negative pressure to a wound area under the typical pressures used in negative pressure therapy, for example between 40 to 150 mmHg. In some embodiments, the wicking fabric may comprise several layers of material stacked or layered over each other, which may in some cases be useful in preventing the fluid passage 212 from collapsing under the application of negative pressure. In other embodiments, the wicking fabric used in the fluid passage 212 may be between 1.5 mm and 6 mm; more preferably, the wicking fabric may be between 3 mm and 6 mm thick, and may be comprised of either one or several individual layers of wicking fabric. In other embodiments, the fluid passage 212 may be between 1.2-3 mm thick, and preferably thicker than 1.5 mm. Some embodiments, for example a suction adapter used with a dressing which retains liquid such as wound exudate, may employ hydrophobic layers in the fluid passage 212, and only gases may travel through the fluid passage 212. Additionally, and as described previously, the materials used in the system are preferably conformable and soft, which may help to avoid pressure ulcers and other complications which may result from a wound treatment system being pressed against the skin of a patient.

Preferably, the filter element 214 is impermeable to liquids, but permeable to gases, and is provided to act as a liquid bather and to ensure that no liquids are able to escape from the wound dressing 100. The filter element 214 may also function as a bacterial bather. Typically the pore size is 0.2 μm. Suitable materials for the filter material of the filter element 214 include 0.2 micron Gore™ expanded PTFE from the MMT range, PALL Versapore™ 200R, and Donaldson™ TX6628. Larger pore sizes can also be used but these may require a secondary filter layer to ensure full bioburden containment. As wound fluid contains lipids it is preferable, though not essential, to use an oleophobic filter membrane for example 1.0 micron MMT-332 prior to 0.2 micron MMT-323. This prevents the lipids from blocking the hydrophobic filter. The filter element can be attached or sealed to the port and/or the cover film over the orifice. For example, the filter element 214 may be molded into the fluidic connector 110, or may be adhered to one or both of the top of the cover layer and bottom of the suction adapter 110 using an adhesive such as, but not limited to, a UV cured adhesive.

It will be understood that other types of material could be used for the filter element 214. More generally a microporous membrane can be used which is a thin, flat sheet of polymeric material, this contains billions of microscopic pores. Depending upon the membrane chosen these pores can range in size from 0.01 to more than 10 micrometers. Microporous membranes are available in both hydrophilic (water filtering) and hydrophobic (water repellent) forms. In some embodiments of the invention, filter element 214 comprises a support layer and an acrylic co-polymer membrane formed on the support layer. Preferably the wound dressing 100 according to certain embodiments of the present invention uses microporous hydrophobic membranes (MHMs). Numerous polymers may be employed to form MHMs. For example, the MHMs may be formed from one or more of PTFE, polypropylene, PVDF and acrylic copolymer. All of these optional polymers can be treated in order to obtain specific surface characteristics that can be both hydrophobic and oleophobic. As such these will repel liquids with low surface tensions such as multi-vitamin infusions, lipids, surfactants, oils and organic solvents.

MHMs block liquids whilst allowing air to flow through the membranes. They are also highly efficient air filters eliminating potentially infectious aerosols and particles. A single piece of MHM is well known as an option to replace mechanical valves or vents. Incorporation of MHMs can thus reduce product assembly costs improving profits and costs/benefit ratio to a patient.

The filter element 214 may also include an odor absorbent material, for example activated charcoal, carbon fiber cloth or Vitec Carbotec-RT Q2003073 foam, or the like. For example, an odor absorbent material may form a layer of the filter element 214 or may be sandwiched between microporous hydrophobic membranes within the filter element. The filter element 214 thus enables gas to be exhausted through the orifice. Liquid, particulates and pathogens however are contained in the dressing.

The wound dressing 100 may comprise spacer elements 215 in conjunction with the fluidic connector 110 and the filter 214. With the addition of such spacer elements 215 the fluidic connector 110 and filter 214 may be supported out of direct contact with the absorbent layer 220 and/or the transmission layer 226. The absorbent layer 220 may also act as an additional spacer element to keep the filter 214 from contacting the transmission layer 226. Accordingly, with such a configuration contact of the filter 214 with the transmission layer 226 and wound fluids during use may thus be minimized.

Similar to the embodiments of wound dressings described above, some wound dressings comprise a perforated wound contact layer with silicone adhesive on the skin-contact face and acrylic adhesive on the reverse. Above this bordered layer sits a transmission layer or a 3D spacer fabric pad. Above the transmission layer, sits an absorbent layer. The absorbent layer can include a superabsorbent non-woven (NW) pad. The absorbent layer can over-border the transmission layer by approximately 5 mm at the perimeter. The absorbent layer can have an aperture or through-hole toward one end. The aperture can be about 10 mm in diameter. Over the transmission layer and absorbent layer lies a backing layer. The backing layer can be a high moisture vapor transmission rate (MVTR) film, pattern coated with acrylic adhesive. The high MVTR film and wound contact layer encapsulate the transmission layer and absorbent layer, creating a perimeter border of approximately 20 mm. The backing layer can have a 10 mm aperture that overlies the aperture in the absorbent layer. Above the hole can be bonded a fluidic connector that comprises a liquid-impermeable, gas-permeable semi-permeable membrane (SPM) or filter that overlies the aforementioned apertures.

In some embodiments, the wound dressings comprise a specific shape to confirm to an area of the body. The shape of the wound dressing can be tailored to a particular type of wound or a specific surgical incision to be treated. For example, wound dressings can be provided in specific shapes and sizes for application on post-breast surgeries. FIGS. 3A-B illustrate embodiments of wound dressings with shapes that can be used for treatment after breast surgery. FIG. 3A illustrates an embodiment of a wound dressing 300 having a T shape. The T-shaped dressing can include an elongate portion 351, which may be rectangular in shape, and a bridging portion 352, which may also be rectangular in shape. The bridging portion 352 extends upwardly from the middle of the elongate portion 351 to form the T shape. The bridging portion 352 can have a first end 353 where the elongate portion 351 and the bridging portion 352 meet. The elongate portion 351 and bridging portion 352 can form a substantially right angle at the section where the elongate portion 351 and bridging portion 352 meet at the first end 353. The bridging portion 352 can have a second end 354 at the end of the bridging portion 352 that is opposite the first end 353.

In some embodiments, the wound dressing 300 has a length that runs along a longitudinal axis of the elongate portion and a width that runs perpendicular to the length. In some embodiments, the length of the elongate portion 351 is greater than the width of the elongate portion 351. In some embodiments, the length of the bridging portion 352 is less than or equal to the width of the bridging portion 352.

The wound dressing 300 can be a layered dressing similar to the wound dressings described with reference to FIG. 2B. The wound dressing 300 can include wound contact layer (not shown), transmission layer (not shown), an absorbent layer 321, filter (not shown), and a backing layer 320 as described herein. The wound contact layer can be in contact with the wound surface. The transmission layer and absorbent layer 321 can be above the wound contact layer as described herein.

As shown in FIG. 3A, each layer of the T shaped dressing can comprise a T shape. For example, the absorbent layer 321 and underlying transmission layer can be T shaped as illustrated in FIG. 3A. The backing layer 320 and wound contact layer can have the same shape as the absorbent layer and transmission layer but can be larger to provide a perimeter 350 that extends beyond the edge of the absorbent and transmission layer. The backing layer 320 and the wound contact layer can be sealed at the perimeter 350 enclosing the transmission layer and absorbent layer 321 between. For example, the backing layer 320 and wound contact layer can have a T shape with a sealed perimeter 350 that can enclose the T-shaped transmission layer and absorbent layer 321 between.

A fluidic connector or port 310 can be placed over an opening in the backing layer 320 to communicate negative pressure to the wound dressing. The fluidic connector or port 310 is similar to the fluidic connector 110 as described with reference to FIGS. 1A-B and 2A-B herein. The port 310 can be positioned on the bridging portion 352 of the T-shaped wound dressing. As shown in FIG. 3A, the port 310 can be positioned at the second end 354 of the bridging portion 352. The T-shaped dressing can be sized and configured to be used as a dressing for a single breast. In other embodiments, the dressing can be made larger and be sized and configured to be positioned over both breasts with the bridge portion positioned between the breasts. FIG. 3B illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a two lobe T shape. The dressing illustrated in FIG. 3B can have a substantially T shape similar to FIG. 3A with an elongated portion 351 and a bridging portion 352 extending upwardly from the middle of the elongate portion forming the T shape. The bridging portion can have a substantially rectangular shape. The lobed T-shaped dressing can have an elongate portion 351 that has two lobes 351a, 351b. The two lobes can have a curved shape as illustrated in FIG. 3B to shape around the breast or other area of the body. The bridging portion 352 can be connected to the two lobes 351a, 351b at a first end 353 of the bridging portion.

The lobed T-shaped wound dressing 300 of FIG. 3B can include a wound contact layer (not shown), a transmission layer (not shown), an absorbent layer 321, filter (not shown), and a backing layer 320 as described herein. The wound contact layer can be in contact with the wound surface. The transmission layer and absorbent layer 321 can be above the wound contact layer as described herein. As shown in FIG. 3B, each layer of the lobed T-shaped dressing can comprise the same shape. For example, the absorbent layer 321 and underlying transmission layer can have the two lobed shape with the bridging portion 352 and the first end 353 as illustrated in FIG. 3B. The backing layer 320 and wound contact layer can have the same shape as the absorbent layer and transmission layer but can be larger to provide a perimeter 350 that extends beyond the edge of the absorbent and transmission layer. The backing layer 320 and the wound contact layer can be sealed at the perimeter 350 enclosing the transmission layer and absorbent layer 321 between. The absorbent layer 321 (and/or the underlying transmission layer) can be a continuous layer between the bridging portion and the elongate portion. For example, the absorbent layer and/or the transmission layer can be one piece of material that is continuous from the port and extend along the bridge portion and can have a narrow portion that extends between the two lobes at the first end 353 as shown in FIG. 3B.

The two lobed wound dressing can have a length that runs along a longitudinal axis of the elongate portion and a width that runs perpendicular to the length. In some embodiments, each lobe 351a and 351b of the elongate portion can have a length that is greater than the width of the lobe. The bridging portion 352 can have a length that is less than or equal to the width. The lobes 351a and 351b can have a lower edge 355a, 355b that is furthest from the port 310. The lower edges 355a, 355b can have a curved shape. In some embodiments the lower edges 355a, 355b can be curved away from the port as shown in FIG. 3B. The lobes 351a and 351b can have as upper edge 356a, 356b that is opposite from the lower edge 355a, 355b. The upper edges 356a, 356b can have the same or substantially the same curvature as the lower edges 355a, 355b.

The bridging portion 352 can include a fluidic connector or port 310 at an opening in the backing layer 320. The fluidic connector or port 310 can be positioned at a second end 354 that is on the opposite end of the bridging portion 352 from the first end 355. The first end 355 communicates negative pressure from the port or fluidic connector 310 through the bridging portion to the two lobes 351a, 351b. The two lobes 351a, 351b of the lobed T-shaped dressing can be used as a single dressing that would cover both breasts. For example, lobe 351a can be used to cover the left breast of the patient while lobe 351b can be used to cover the right breast of the patient. In some embodiments, the single dressing that covers both breasts can have a bra shaped configuration similar to the shaped illustrated in FIG. 3B.

FIG. 3C illustrates an embodiment of the dressing covering surgical incision sites, illustrated in dashed lines. In some embodiments, the dressing of FIG. 3A includes a T-shape that is arranged to fit the T-shaped incision site for breast surgery. FIG. 3D illustrates an example of a surgical breast procedure and the corresponding incision lines shown post breast surgery. As can be seen in FIG. 3D, the incision can include a T-shaped incision that runs along the lower part of the breast. In some embodiments, this can be similar to an inframammary incision at the lower part of the breast where it meets the chest wall. An additional incision can be perpendicular to the lower section of the breast and extend toward the areola. In some procedures, an incision can be made around the nipple or areola. In some embodiments, this incision can be a periareolar incision. FIG. 3C illustrates surgical incision sites as shown by the dashed lines with relation to the T-shaped dressing of FIG. 3A. The T-shaped dressing can be used to fit over the surgical incision on a single breast. The elongated portion 351 of the dressing can be positioned to cover the incision at the lower section of the breast. The bridging portion 352 of the dressing can be positioned on the incision that extends from the lower section of the breast to the nipple or areola. As shown in FIG. 3C, in some embodiments, the port 310 at the second end 354 of the bridging portion 352 can be positioned on the area of the dressing that is over the incision around the areola.

FIG. 3E illustrates an embodiment of a two lobe wound dressing. The dressing illustrated in FIG. 3E can be bra-shaped similar to FIG. 3B with two lobes, one for each breast and a bridging portion 352 extending upwardly at an intersection between the two lobes. The bridging portion can have a substantially rectangular shape. The lobed bra-shaped dressing can have two lobes 381a, 381b. The two lobes can have a curved shape as illustrated in FIG. 3E to shape around the breast or other area of the body. The bridging portion 352 can be connected to the two lobes 381a, 381b at a first end 353 of the bridging portion located at the intersection between the two lobes. The two lobed wound dressing of FIG. 3E is similar to the two lobed wound dressing of FIG. 3B, however, the two lobed wound dressing of FIG. 3E has two circular or oval shaped lobes. The lobes 381a, 381b can be circular or oval in shape and can be fluidically connected to each other by a bridging portion 352.

The two lobe wound dressing 300 of FIG. 3E can include a wound contact layer (not shown), a transmission layer (not shown), an absorbent layer 321, filter (not shown), and a backing layer 320 as described herein. The wound contact layer can be in contact with the wound surface. The transmission layer and absorbent layer 321 can be above the wound contact layer as described herein. As shown in FIG. 3E, each layer of the lobed dressing can comprise the same shape. For example, the absorbent layer 321 and underlying transmission layer can have the two lobed shape with the bridging portion 352 and the first end 353 as illustrated in FIG. 3E. The backing layer 320 and wound contact layer can have the same shape as the absorbent layer and transmission layer but can be larger to provide a perimeter 350 that extends beyond the edge of the absorbent and transmission layer. The backing layer 320 and the wound contact layer can be sealed at the perimeter 350 enclosing the transmission layer and absorbent layer 321 between. The absorbent layer 321 (and/or the underlying transmission layer) can be a continuous layer between the bridging portion and the elongate portion. For example, the absorbent layer and/or the transmission layer can be one piece of material that is continuous from the port and extend along the bridge portion and can have a Y-shaped narrow portion that extends between the two lobes at the first end 353 as shown in FIG. 3E.

The bridging portion 352 can include a fluidic connector or port 310 at an opening in the backing layer 320. The fluidic connector or port 310 can be positioned at a second end 354 that is on the opposite end of the bridging portion 352 from the first end 353. The first end 353 communicates negative pressure from the port or fluidic connector 310 through the bridging portion to the two lobes 381a, 381b. The two lobes 381a, 381b of the lobed dressing can be used as a single dressing that would cover both breasts. For example, lobe 381a can be used to cover the left breast of the patient while lobe 381b can be used to cover the right breast of the patient and the bridging portion 352 positioned between the two lobes. In some embodiments, the single dressing that covers both breasts can have the circular shape configuration similar to the shaped illustrated in FIG. 3E.

FIG. 3F illustrates an embodiment of a triangular shaped dressing that can be one dressing that is used for both breasts. FIG. 3F illustrates an embodiment of a negative pressure wound treatment system employing a wound dressing with a two triangular shaped lobed dressing. The dressing illustrated in FIG. 3F can have two lobes 371a, 371b with a substantially triangular shape. The dressing can have an elongate portion 351 and a bridging portion 352 in the middle of the elongate portion between the two lobes. The two triangular shaped lobe dressing can have an elongate portion 351 that has two lobes 371a, 371b. The two lobes can each have a substantially triangular shape as illustrated in FIG. 3F to shape around the surgical incisions of the breast as shown in FIG. 3D or other area of the body. The bridging portion 352 can be connected to the two lobes 371a, 371b with the first lobe 371a on a first side of the bridging portion 352 and a second lobe 371b on a second side of the bridging portion 352 as shown in FIG. 3F. FIG. 3F illustrates an embodiment of the wound dressing with the fluid connector 310 extending downward from the elongate portion 351 and away from the middle of the breasts. In some embodiments, the dressing can be positioned over both breasts with the fluidic connector positioned between the breasts as illustrated in FIGS. 3B and 3E.

The triangular shaped lobed wound dressing 300 of FIG. 3F can include a wound contact layer (not shown), a transmission layer (not shown), an absorbent layer 321, filter (not shown), and a backing layer 320 as described herein. The wound contact layer can be in contact with the wound surface. The transmission layer and absorbent layer 321 can be above the wound contact layer as described herein. As shown in FIG. 3F, each layer of the triangular shaped lobe dressing can comprise the same shape. For example, the absorbent layer 321 and underlying transmission layer can have the two lobed shape with the bridging portion 352 as illustrated in FIG. 3F. The backing layer 320 and wound contact layer can have the same shape as the absorbent layer and transmission layer but can be larger to provide a perimeter 350 that extends beyond the edge of the absorbent and transmission layer. The backing layer 320 and the wound contact layer can be sealed at the perimeter 350 enclosing the transmission layer and absorbent layer 321 between. The absorbent layer 321 (and/or the underlying transmission layer) can be a continuous layer between the bridging portion and the elongate portion.

The two triangular shaped lobed wound dressing can have a length that runs along a longitudinal axis of the elongate portion and a width that runs perpendicular to the length. The lobes 371a and 371b can have edges 361 and corners 362. In some embodiments, each lobe 371a and 371b of the elongate portion can have a long edge 363 that extends along the longitudinal axis on the lower portion of the dressing. The long edge 363 forms an edge of the first lobe 371a and the second lobe 371b and a lower portion of the bridging portion 352.

The bridging portion 352 can include a fluidic connector or port 310 at an opening in the backing layer 320. The fluidic connector or port 310 can be positioned at the bridging portion 352 between the two lobes 371a, 371b. The bridging portion 352 communicates negative pressure from the port or fluidic connector 310 through the bridging portion to the two lobes 371a, 371b.

As shown in FIG. 3F, the dressing can be positioned over both breasts with the port or fluidic connector 310 positioned on the bridging portion between the breasts. The two triangular shaped portions 371a, 371b can each cover a single breast. The two lobes 371a, 371b of the triangular shaped lobed dressing can be used as a single dressing that would cover both breasts. For example, lobe 371a can be used to cover the left breast of the patient while lobe 371b can be used to cover the right breast of the patient with the bridging portion 352 between the two lobes.

FIG. 3G illustrates an embodiment of a triangular shaped wound dressing. The wound dressing 300 can be a layered dressing similar to the wound dressings described with reference to FIG. 2B. The triangular shaped dressing can have edges 361 and corners 362. The wound dressing 300 can include wound contact layer (not shown), transmission layer (not shown), an absorbent layer 321, filter (not shown), and a backing layer 320 as described herein. The wound contact layer can be in contact with the wound surface. The transmission layer and absorbent layer 321 can be above the wound contact layer as described herein.

As shown in FIG. 3G, each layer of the triangular shaped dressing can comprise a triangular shape. For example, the absorbent layer 321 and underlying transmission layer can be triangular shaped as illustrated in FIG. 3G. The backing layer 320 and wound contact layer can have the same shape as the absorbent layer and transmission layer but can be larger to provide a perimeter 350 that extends beyond the edge of the absorbent and transmission layer. The backing layer 320 and the wound contact layer can be sealed at the perimeter 350 enclosing the transmission layer and absorbent layer 321 between. For example, the backing layer 320 and wound contact layer can have a triangular shape with a sealed perimeter 350 that can enclose the triangular shaped transmission layer and absorbent layer 321 between.

Embodiments of the wound dressings, wound dressing components, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in International Application No. PCT/GB2014/050781, filed Mar. 14, 2014, published as WO2014/140606A1 on Sep. 18, 2014, titled “WOUND DRESSING AND METHOD OF TREATMENT,” the disclosure of which is hereby incorporated by reference in its entirety, including further details relating to the bridging between different portions of the wound dressing which may be applicable to bridging of the absorbent layer and/or transmission layer between the elongate portion and the bridging portion of FIGS. 3A-3C and FIGS. 3E-3G. Additional embodiments of the wound dressings, wound dressing components, wound treatment apparatuses and methods described herein may also be used in combination or in addition to those described in U.S. Publication No. 2014/0350494 A1, the entirety of which is hereby incorporated by reference.

FIGS. 4A-D illustrate the use of an embodiment of a negative pressure therapy wound treatment system being used to treat a wound site on a patient. Although these figures do not illustrate a wound treatment system such as described in FIGS. 3A-3C and FIGS. 3E-3G, it will be appreciated that similar steps may be utilized to treat post-surgical breast wounds. FIG. 4A shows a wound site 400 being cleaned and prepared for treatment. Here, the healthy skin surrounding the wound site 400 is preferably cleaned and excess hair removed or shaved. The wound site 400 may also be irrigated with sterile saline solution if necessary. Optionally, a skin protectant may be applied to the skin surrounding the wound site 400. If necessary, a wound packing material, such as foam or gauze, may be placed in the wound site 400. This may be preferable if the wound site 400 is a deeper wound.

After the skin surrounding the wound site 400 is dry, and with reference now to FIG. 4B, the wound dressing 100 may be positioned and placed over the wound site 400. Preferably, the wound dressing 100 is placed with the wound contact layer over and/or in contact with the wound site 400. In some embodiments, an adhesive layer is provided on the lower surface of the wound contact layer, which may in some cases be protected by an optional release layer to be removed prior to placement of the wound dressing 100 over the wound site 400. Preferably, the dressing 100 is positioned such that the fluidic connector 110 is in a raised position with respect to the remainder of the dressing 10 so as to avoid fluid pooling around the port. In some embodiments, the dressing 100 is positioned so that the fluidic connector 110 is not directly overlying the wound, and is level with or at a higher point than the wound. To help ensure adequate sealing for TNP, the edges of the dressing 100 are preferably smoothed over to avoid creases or folds.

With reference now to FIG. 4C, the dressing 10 is connected to the pump 150. The pump 150 is configured to apply negative pressure to the wound site via the dressing 100, and typically through a conduit. In some embodiments, and as described herein, a fluidic connector 110 may be used to join the conduit 190 from the pump to the dressing 100. Where the fluidic connector is adhered to the top layer of the wound dressing, a length of tubing may be coupled at a first end of the fluidic connector such that the tubing, or conduit, extends away from the fluidic connector parallel to the top of the dressing. In some embodiments the conduit may comprise a fluidic connector. It is expressly contemplated that a conduit may be a soft bridge, a hard tube, or any other apparatus which may serve to transport fluid. Upon the application of negative pressure with the pump 150, the dressing 100 may in some embodiments partially collapse and present a wrinkled appearance as a result of the evacuation of some or all of the air underneath the dressing 100. In some embodiments, the pump 150 may be configured to detect if any leaks are present in the dressing 100, such as at the interface between the dressing 100 and the skin surrounding the wound site 400. Should a leak be found, such leak is preferably remedied prior to continuing treatment.

Turning to FIG. 4D, additional fixation strips 410 may also be attached around the edges of the dressing 100. Such fixation strips 410 may be advantageous in some situations so as to provide additional sealing against the skin of the patient surrounding the wound site 400. For example, the fixation strips 410 may provide additional sealing for when a patient is more mobile. In some cases, the fixation strips 410 may be used prior to activation of the pump 150, particularly if the dressing 100 is placed over a difficult to reach or contoured area.

Treatment of the wound site 400 preferably continues until the wound has reached a desired level of healing. In some embodiments, it may be desirable to replace the dressing 100 after a certain time period has elapsed, or if the dressing is full of wound fluids. During such changes, the pump 150 may be kept, with just the dressing 100 being changed.

In some embodiments, one or more wound dressings can be used to treat multiple wound or surgical sites. For example, two of the single breast dressings shown in FIGS. 3A and 3G can be used to treat post-breast surgery sites. As described above one dressing can be placed over the left breast and one dressing can be placed over the right breast. Each of the single breast dressings can include a fluidic connector or port 310 connected to and extending from the dressing as shown in FIGS. 3A and 3G. The fluidic connector or port 310 is similar to the fluidic connector 110 as described with reference to FIGS. 1A-B and 2A-B herein. As described above with reference to FIGS. 3A and 3G, the fluidic connector or port 310 can be positioned on the dressing. The dressing can be T-shaped or triangular as illustrated in FIGS. 3A and 3G, respectively, or can be any other shape utilized for wound dressings including, but not limited to, rectangular, square, or circular dressing shapes. The T-shaped or triangular shaped dressing can be positioned over the T-shaped incision similar to the incision shown in FIGS. 3C-3D as described herein.

When multiple dressings are used to cover the multi-surgery sites, the two or more dressings used in combination can be referred to collectively as a multisite dressing. The multisite dressing can be utilized after a breast surgery as described previously.

FIGS. 3A and 3G illustrate the fluid connector or port 310 extending from the dressing. The multisite dressing can include two dressings used to cover the multiple surgical sites. Each dressing can include a fluid connector or port 310 extending from the dressings for connection to a conduit and/or pump to apply negative pressure to the wound site as described herein. The fluid connector can include a coupling 160 disposed at the proximal end of the fluidic connector. As described with reference to FIGS. 1A-1B, the pump can be connected via a tube to the coupling or can be directly connected to the coupling.

In some embodiments, to minimize the bulk and weight carried by the patient the two fluidic connectors can be connected to a single pump by utilizing a multisite connector. For example, in some embodiments, two dressings can include two fluidic connectors and couplings, one extending from each of the dressings, and the two fluidic connectors can be connected to the single pump with a Y-shaped connector. The Y-shaped connector can be provided in a kit with multisite dressings. In some embodiments, for use in post-breast surgery applications, the Y-shaped connector can be provided in a kit with two dressings, one dressing for each breast, and a pump. In some embodiments, the pump, multi-site dressing, and multisite connector can be used for other surgeries including but not limited to donor site surgeries.

FIGS. 5A and 5B illustrate an embodiment of a Y-shaped connector that can be used with a multisite dressing. The Y-shaped connector can include three conduit attachment portions 1104, 1105, 1103. A pump conduit attachment portion 1103 can be used to connect to a conduit or tubing extending from a pump or to connect to the pump itself. The pump conduit attachment portion 1103 can include a male non-luer connector at a proximal end of the Y-shaped connector. The male connector can attach to a female connector of a conduit or pump. The pump conduit attachment portion 1103 has a shaft 1106 extending from the attachment portion and forming the bottom portion of the Y shape of the connector.

The Y-shaped connector also includes two dressing conduit attachment portions 1104, 1105. The dressing conduit attachment portions 1104, 1105 can be used to connect to the coupling of the fluidic connector extending from a dressing. In some embodiments, a conduit or tubing can be used to connect the fluidic connector to the Y-shaped connector. The conduit or tubing may be a soft bridge, a hard tube, or any other apparatus which may serve to transport fluid. The conduit or tubing can include a coupling at a proximal end and at a distal end. The conduit or tubing can be connected to the coupling of the fluidic connector at the distal end and connected to the conduit attachment portions of the Y-shaped connector at the proximal end of the conduit.

The dressing conduit attachment portion 1104, 1105 can include a female non-luer connector at a distal end of the Y-shaped connector. The female connector can attach to a male connector of the coupling of the fluidic connector or to the coupling of the conduit. In some embodiments, the fluidic connector or the conduit can include a clamp, cap, or other closure mechanism to allow the user to monitor or change one dressing while the other dressing continues to apply negative pressure. In some embodiments the closure mechanism can be a valve, for example, a non-return valve. The dressing conduit attachment portions 1104, 1105 include shafts 1102, 1107, respectively, forming the top portions of the Y shape of the connector as shown in FIGS. 5A-5B. The proximal ends of shafts 1102, 1107 and the distal end of shaft 1106 meet at a joint 1101. In some embodiments, the joint 1101 can include a hinge that allows rotation of the shafts 1102, 1107, 1106 about the joint 1101. In some embodiments, only shafts 1102, 1107 of the dressing conduit attachment portions can more relative to the joint 1101 and the shaft 1106 of the pump conduit attachment portion is fixed. In some embodiments, the whole Y-shaped connector will be in two parts that allow 360° rotation. FIG. 5C illustrates an embodiment of the Y-shaped connector that is formed of two freely-rotating parts that allow rotation of each part relative to the other. The rotation of the Y-shaped connector can allow the user to twist the pump around while the dressings and conduits extending from the dressing remain stationary.

In some embodiments, the male and female non-luer connectors can be a rigid plastic. In some embodiments, the shafts 1106, 1102, 1107 can be a flexible plastic tubing. In some embodiments, the Y-shaped connector can be encased in a soft silicone sleeve to increase patient comfort and prevent the Y-shaped connector from becoming a pressure point.

Utilizing the Y-shaped connector illustrated in FIGS. 5A-5B to attach a single pump to the two dressings, the pump can draw pressure in the two dressings simultaneously. The performance and fluid management of the multisite dressing and Y-connector is equivalent to a control test of the standard single dressing with single pump set-up.

All of the features disclosed in this specification (including any accompanying exhibits, claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The disclosure is not restricted to the details of any foregoing embodiments. The disclosure extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

Various modifications to the implementations described in this disclosure may be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other implementations without departing from the spirit or scope of this disclosure. Thus, the disclosure is not intended to be limited to the implementations shown herein, but is to be accorded the widest scope consistent with the principles and features disclosed herein. Certain embodiments of the disclosure are encompassed in the claim set listed below or presented in the future.

Number	Name	Date	Kind
3929135	Thompson	Dec 1975	A
3972328	Chen	Aug 1976	A
4029598	Neisius et al.	Jun 1977	A
4728499	Fehder	Mar 1988	A
4813942	Alvarez	Mar 1989	A
5000172	Ward	Mar 1991	A
5056510	Gilman	Oct 1991	A
5106629	Cartmell et al.	Apr 1992	A
5181905	Flam	Jan 1993	A
5238732	Krishnan	Aug 1993	A
5447492	Cartmell et al.	Sep 1995	A
5549584	Gross	Aug 1996	A
5605165	Sessions et al.	Feb 1997	A
5707499	Joshi et al.	Jan 1998	A
5759570	Arnold	Jun 1998	A
5852126	Barnard et al.	Dec 1998	A
5960795	Schultz	Oct 1999	A
6008429	Ritger	Dec 1999	A
6071267	Zamierowski	Jun 2000	A
6345623	Heaton et al.	Feb 2002	B1
6458109	Henley et al.	Oct 2002	B1
6626891	Ohmstede	Sep 2003	B2
6685681	Lockwood et al.	Feb 2004	B2
6752794	Lockwood et al.	Jun 2004	B2
6936037	Bubb et al.	Aug 2005	B2
6951553	Bubb et al.	Oct 2005	B2
6979324	Bybordi et al.	Dec 2005	B2
7004915	Boynton et al.	Feb 2006	B2
7070584	Johnson et al.	Jul 2006	B2
7108683	Zamierowski	Sep 2006	B2
7216651	Argenta et al.	May 2007	B2
7338482	Lockwood et al.	Mar 2008	B2
7361184	Joshi	Apr 2008	B2
7381859	Hunt et al.	Jun 2008	B2
7485112	Karpowicz et al.	Feb 2009	B2
7569742	Haggstrom et al.	Aug 2009	B2
7605298	Bechert et al.	Oct 2009	B2
7615036	Joshi et al.	Nov 2009	B2
7622629	Aali	Nov 2009	B2
7625362	Boehringer et al.	Dec 2009	B2
7699823	Haggstrom et al.	Apr 2010	B2
7700819	Ambrosio et al.	Apr 2010	B2
7708724	Weston	May 2010	B2
7718249	Russell et al.	May 2010	B2
7722582	Lina et al.	May 2010	B2
7749531	Booher	Jul 2010	B2
7759537	Bishop et al.	Jul 2010	B2
7759539	Shaw et al.	Jul 2010	B2
7775998	Riesinger	Aug 2010	B2
7779625	Joshi et al.	Aug 2010	B2
7846141	Weston	Dec 2010	B2
7910791	Coffey	Mar 2011	B2
7922703	Riesinger	Apr 2011	B2
7945302	McAdams	May 2011	B2
7959624	Riesinger	Jun 2011	B2
7964766	Blott et al.	Jun 2011	B2
7976519	Bubb et al.	Jul 2011	B2
8021347	Vitaris et al.	Sep 2011	B2
8034037	Adams et al.	Oct 2011	B2
8062272	Weston	Nov 2011	B2
8062331	Zamierowski	Nov 2011	B2
8152785	Vitaris	Apr 2012	B2
8162907	Heagle	Apr 2012	B2
8235972	Adahan	Aug 2012	B2
8241261	Randolph et al.	Aug 2012	B2
8372049	Jaeb et al.	Feb 2013	B2
8372050	Jaeb et al.	Feb 2013	B2
8425478	Olson	Apr 2013	B2
8444611	Wilkes et al.	May 2013	B2
8513481	Gergely et al.	Aug 2013	B2
8540688	Eckstein et al.	Sep 2013	B2
8545466	Andresen et al.	Oct 2013	B2
8568386	Malhi	Oct 2013	B2
8641691	Fink et al.	Feb 2014	B2
8663198	Buan et al.	Mar 2014	B2
8682442	McAdams	Mar 2014	B2
8715256	Greener	May 2014	B2
8751180	Lull et al.	Jun 2014	B2
8764732	Hartwell	Jul 2014	B2
8795247	Bennett et al.	Aug 2014	B2
8795800	Evans	Aug 2014	B2
8808274	Hartwell	Aug 2014	B2
8834451	Blott et al.	Sep 2014	B2
8834452	Hudspeth et al.	Sep 2014	B2
8974429	Gordon et al.	Mar 2015	B2
9012714	Fleischmann	Apr 2015	B2
9061095	Adie et al.	Jun 2015	B2
9067003	Buan et al.	Jun 2015	B2
9127665	Locke et al.	Sep 2015	B2
9199012	Vitaris et al.	Dec 2015	B2
9283118	Locke et al.	Mar 2016	B2
9421309	Robinson et al.	Aug 2016	B2
9427505	Askem et al.	Aug 2016	B2
9526439	Connelly et al.	Dec 2016	B2
9681993	Wu et al.	Jun 2017	B2
9682179	May	Jun 2017	B2
9829471	Hammond et al.	Nov 2017	B2
10046096	Askem et al.	Aug 2018	B2
10058642	Weston	Aug 2018	B2
10155070	Childress et al.	Dec 2018	B2
10328188	Deutsch et al.	Jun 2019	B2
20020062114	Murai et al.	May 2002	A1
20030125646	Whitlock	Jul 2003	A1
20040015115	Sinyagin	Jan 2004	A1
20040057855	Gerlach et al.	Mar 2004	A1
20050004501	Lorenzo	Jan 2005	A1
20050209574	Boehringer et al.	Sep 2005	A1
20050222527	Miller et al.	Oct 2005	A1
20050288691	Leiboff	Dec 2005	A1
20060009744	Erdman et al.	Jan 2006	A1
20070016152	Karpowicz et al.	Jan 2007	A1
20070040454	Freudenberger et al.	Feb 2007	A1
20070055209	Patel et al.	Mar 2007	A1
20070219497	Johnson et al.	Sep 2007	A1
20070219512	Heaton et al.	Sep 2007	A1
20070225663	Watt et al.	Sep 2007	A1
20070255194	Gudnason et al.	Nov 2007	A1
20080031748	Ihle et al.	Feb 2008	A1
20080132821	Propp et al.	Jun 2008	A1
20080200096	Thornton	Aug 2008	A1
20080306456	Riesinger	Dec 2008	A1
20090125004	Shen et al.	May 2009	A1
20090157024	Song	Jun 2009	A1
20090234306	Vitaris	Sep 2009	A1
20090293887	Wilkes et al.	Dec 2009	A1
20090299251	Buan	Dec 2009	A1
20090299306	Buan	Dec 2009	A1
20100125258	Coulthard et al.	May 2010	A1
20100259406	Caso et al.	Oct 2010	A1
20100268111	Drinan et al.	Oct 2010	A1
20100318052	Ha et al.	Dec 2010	A1
20110004172	Eckstein et al.	Jan 2011	A1
20110224631	Simmons et al.	Sep 2011	A1
20110313339	Vitaris	Dec 2011	A1
20120051945	Orndorff et al.	Mar 2012	A1
20120123358	Hall et al.	May 2012	A1
20120136325	Allen et al.	May 2012	A1
20120190956	Connolly	Jul 2012	A1
20120209226	Simmons et al.	Aug 2012	A1
20130066285	Locke et al.	Mar 2013	A1
20130066289	Song et al.	Mar 2013	A1
20130090616	Neubauer	Apr 2013	A1
20130144227	Locke et al.	Jun 2013	A1
20130150813	Gordon et al.	Jun 2013	A1
20130165878	Heagle	Jun 2013	A1
20130296762	Toth	Nov 2013	A1
20130302545	Schnelker et al.	Nov 2013	A1
20140114268	Auguste et al.	Apr 2014	A1
20140200533	Whyte et al.	Jul 2014	A1
20140228789	Wilkes	Aug 2014	A1
20140316359	Collinson et al.	Oct 2014	A1
20140332088	Senesh	Nov 2014	A1
20140350494	Hartwell	Nov 2014	A1
20150032035	Banwell et al.	Jan 2015	A1
20150119831	Robinson et al.	Apr 2015	A1
20150119832	Locke	Apr 2015	A1
20150119833	Coulthard et al.	Apr 2015	A1
20150231021	Smith	Aug 2015	A1
20160000611	Niederauer et al.	Jan 2016	A1
20160045377	Robinson et al.	Feb 2016	A1
20160081580	Bergelin et al.	Mar 2016	A1
20160101282	Bergelin et al.	Apr 2016	A1
20160120706	Collinson et al.	May 2016	A1
20160287763	Simmons et al.	Oct 2016	A1
20160298620	Cordoba et al.	Oct 2016	A1
20170028111	Tumey et al.	Feb 2017	A1
20170156658	Maharbiz et al.	Jun 2017	A1
20170368239	Askem et al.	Dec 2017	A1
20180055359	Shamim et al.	Mar 2018	A1
20180133378	Askem et al.	May 2018	A1
20180168916	Kelch et al.	Jun 2018	A1
20180318476	Askem et al.	Nov 2018	A1
20200121833	Askem et al.	Apr 2020	A9

Number	Date	Country
202822419	Mar 2013	CN
204670041	Sep 2015	CN
3443101	May 1986	DE
0340018	Nov 1989	EP
1476217	Mar 2008	EP
1955887	Aug 2008	EP
2462908	Jun 2012	EP
3037115	Jun 2016	EP
3628289	Nov 2021	EP
1163907	Oct 1958	FR
1255395	Dec 1971	GB
2307180	Jun 2000	GB
2468905	Sep 2010	GB
2014237992	Dec 2014	JP
2016118204	Jun 2016	JP
WO-8300742	Mar 1983	WO
WO-9216245	Oct 1992	WO
WO-9605873	Feb 1996	WO
WO-2004077387	Sep 2004	WO
WO-2005046760	May 2005	WO
WO-2005105180	Nov 2005	WO
WO-2007013049	Feb 2007	WO
WO-2007113597	Oct 2007	WO
WO-2008039223	Apr 2008	WO
WO-2009124100	Oct 2009	WO
WO-2009147402	Dec 2009	WO
WO-2009158128	Dec 2009	WO
WO-2010142959	Dec 2010	WO
WO-2011135285	Nov 2011	WO
WO-2011135286	Nov 2011	WO
WO-2011135287	Nov 2011	WO
WO-2011144888	Nov 2011	WO
WO 2012021553	Feb 2012	WO
WO-2012131237	Oct 2012	WO
WO-2012143665	Oct 2012	WO
WO-2013010907	Jan 2013	WO
WO-2013064852	May 2013	WO
WO-2013078095	May 2013	WO
WO-2013083800	Jun 2013	WO
WO-2013090810	Jun 2013	WO
WO-2013149078	Oct 2013	WO
WO-2014008348	Jan 2014	WO
WO-2014016759	Jan 2014	WO
WO-2014020440	Feb 2014	WO
WO-2014020443	Feb 2014	WO
WO-2014108476	Jul 2014	WO
WO 2014140606	Sep 2014	WO
WO 2014140608	Sep 2014	WO
WO-2015022334	Feb 2015	WO
WO-2015022340	Feb 2015	WO
WO-2015031216	Mar 2015	WO
WO-2015168720	Nov 2015	WO
WO-2016018448	Feb 2016	WO
WO-2016109041	Jul 2016	WO
WO-2016174048	Nov 2016	WO
WO 2017148824	Sep 2017	WO
WO-2017197357	Nov 2017	WO
WO-2018041854	Mar 2018	WO

Number	Date	Country
62380907	Aug 2016	US
62304079	Mar 2016	US
62304010	Mar 2016	US

Negative pressure wound therapy apparatus for post breast surgery wounds

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Term Extension

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

PCT Information

US Referenced Citations (173)

Foreign Referenced Citations (58)

Non-Patent Literature Citations (19)

Related Publications (1)

Provisional Applications (3)

Entry
Advantec MFS, Inc., “Membrane Filters” (catalog), retrieved from http://www.advantecmfs.com/catalog/filt/membrane.pdf, on Jan. 29, 2016, Copyright 2001-2011, 17 pages.
Hersle K., et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies,” The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, pp. 35-37.
International Preliminary Report on Patentability for Application No. PCT/EP2017/054369, dated Sep. 13, 2018, 12 pages.
KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390061 Rev D, Jan. 2010, 10 pages.
KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390153-WEB Rev B, Jan. 2010, 12 pages.
KCI Licensing, “Prevena™ Incision Management System—Patient Guide”, 390064 Rev D, Jan. 2010, 4 pages.
KCI Licensing, “Prevena™ Incision Management System—Patient Guide,” 390152-WEB C, Jan. 2011, 6 pages.
KCI Licensing, Prevena™ Incision Management System, Jun. 22, 2010, in 2 pages.
Kendall ULTEC Hydrocolloid Dressing (4x4″), Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page.
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation).
Smith & Nephew, Allevyn Gentle Border Multisite, Jun. 2011, 2 pages.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System,” Spiral Booklet, Mar. 2011, 7 pages.
Smith and Nephew Inc., “Allevyn Wound Dressings Pamphlet,” 2008, 2 pages.
Smith and Nephew Medical Ltd., “Reach for the Right Dressing. Reach for Allevyn,” Allevyn Educational Booklet, Apr. 2014, 2 pages.
Technology Watch, May 1989, 1 page.
International Search Report and Written Opinion, re PCT Application No. PCT/EP2017/054369, dated Aug. 24, 2017.
KCI, “V.A.C. Therapy Clinical guidelines: A reference source for clinicians”, KCI Ltd., Nov. 2005 (New, revised edition), in 24 pages.
Smith & Nephew, “Clinical Cases—PICO Bilateral Breast Reduction Study”, Aug. 2014, in 8 pages.
U.S. Appl. No. 16/120,056, System for Providing Wound Dressing Port and Associated Wound Dressing, filed Aug. 31, 2018.